Adjuvant Pembrolizumab Maintains Survival Benefit Without Raising New Melanoma Risk in Stage II Disease
Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.